Lithium profoundly prevents brain damage associated with Parkinson's disease, mouse study suggests

Lithium profoundly prevents the aggregation of toxic proteins and cell loss associated with Parkinson's disease (PD) in a mouse model of the condition. Preclinical research is aimed at determining correct dosages for a drug that continues to be the gold standard for treating bipolar disorder. Medical researchers are currently working toward initiating Phase IIa clinical studies of lithium in humans in conjunction with standard PD drug therapy.

Read the whole article on Science Daily

More from Science Daily